Literature DB >> 22525701

Mice expressing activated PI3K rapidly develop advanced colon cancer.

Alyssa A Leystra1, Dustin A Deming, Christopher D Zahm, Mohammed Farhoud, Terrah J Paul Olson, Jamie N Hadac, Laura A Nettekoven, Dawn M Albrecht, Linda Clipson, Ruth Sullivan, Mary Kay Washington, Jose R Torrealba, Jamey P Weichert, Richard B Halberg.   

Abstract

Aberrations in the phosphoinositide 3-kinase (PI3K) signaling pathway play a key role in the pathogenesis of numerous cancers by altering cellular growth, metabolism, proliferation, and apoptosis. Mutations in the catalytic domain of PI3K that generate a dominantly active kinase are commonly found in human colorectal cancers and have been thought to drive tumor progression but not initiation. However, the effects of constitutively activated PI3K upon the intestinal mucosa have not been previously studied in animal models. Here, we show that the expression of a dominantly active form of the PI3K protein in the mouse intestine results in hyperplasia and advanced neoplasia. Mice expressing constitutively active PI3K in the epithelial cells of the distal small bowel and colon rapidly developed invasive adenocarcinomas in the colon that spread into the mesentery and adjacent organs. The histologic characteristics of these tumors were strikingly similar to invasive mucinous colon cancers in humans. Interestingly, these tumors formed without a benign polypoid intermediary, consistent with the lack of aberrant WNT signaling observed. Together, our findings indicate a noncanonical mechanism of colon tumor initiation that is mediated through activation of PI3K. This unique model has the potential to further our understanding of human disease and facilitate the development of therapeutics through pharmacologic screening and biomarker identification.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525701      PMCID: PMC3645915          DOI: 10.1158/0008-5472.CAN-11-4097

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Keratin expression in human tissues and neoplasms.

Authors:  P G Chu; L M Weiss
Journal:  Histopathology       Date:  2002-05       Impact factor: 5.087

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues.

Authors:  Anatoly N Pinchuk; Mark A Rampy; Marc A Longino; R W Scott Skinner; Milton D Gross; Jamey P Weichert; Raymond E Counsell
Journal:  J Med Chem       Date:  2006-04-06       Impact factor: 7.446

4.  Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways.

Authors:  A Klippel; C Reinhard; W M Kavanaugh; G Apell; M A Escobedo; L T Williams
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

5.  Clinicopathological characteristics of mucinous carcinoma of the colon and rectum.

Authors:  T Nozoe; H Anai; S Nasu; K Sugimachi
Journal:  J Surg Oncol       Date:  2000-10       Impact factor: 3.454

6.  Inducible gene knockouts in the small intestinal and colonic epithelium.

Authors:  J R Saam; J I Gordon
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

7.  Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Authors:  Li Zhao; Peter K Vogt
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

8.  Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

Authors:  L K Su; K W Kinzler; B Vogelstein; A C Preisinger; A R Moser; C Luongo; K A Gould; W F Dove
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

9.  APC mutations occur early during colorectal tumorigenesis.

Authors:  S M Powell; N Zilz; Y Beazer-Barclay; T M Bryan; S R Hamilton; S N Thibodeau; B Vogelstein; K W Kinzler
Journal:  Nature       Date:  1992-09-17       Impact factor: 49.962

Review 10.  Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions.

Authors:  Margie Lee Clapper; Harry Stanley Cooper; Wen-Chi Lee Chang
Journal:  Acta Pharmacol Sin       Date:  2007-09       Impact factor: 6.150

View more
  34 in total

1.  Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence.

Authors:  Jamie N Hadac; Alyssa A Leystra; Terrah J Paul Olson; Molly E Maher; Susan N Payne; Alexander E Yueh; Alexander R Schwartz; Dawn M Albrecht; Linda Clipson; Cheri A Pasch; Kristina A Matkowskyj; Richard B Halberg; Dustin A Deming
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

Review 2.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

3.  Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications.

Authors:  Jinru Shia; Nikolaus Schultz; Deborah Kuk; Efsevia Vakiani; Sumit Middha; Neil H Segal; Jaclyn F Hechtman; Michael F Berger; Zsofia K Stadler; Martin R Weiser; Jedd D Wolchok; C Richard Boland; Mithat Gönen; David S Klimstra
Journal:  Mod Pathol       Date:  2016-12-16       Impact factor: 7.842

Review 4.  New insights into the earliest stages of colorectal tumorigenesis.

Authors:  Chelsie K Sievers; William M Grady; Richard B Halberg; Perry J Pickhardt
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-05-26       Impact factor: 3.869

Review 5.  Pathology of rodent models of intestinal cancer: progress report and recommendations.

Authors:  Mary Kay Washington; Anne E Powell; Ruth Sullivan; John P Sundberg; Nicholas Wright; Robert J Coffey; William F Dove
Journal:  Gastroenterology       Date:  2013-02-12       Impact factor: 22.682

Review 6.  The path to metastatic mouse models of colorectal cancer.

Authors:  Gabriele Romano; Sharmeen Chagani; Lawrence N Kwong
Journal:  Oncogene       Date:  2018-02-21       Impact factor: 9.867

Review 7.  Serrated neoplasia-role in colorectal carcinogenesis and clinical implications.

Authors:  Joep E G IJspeert; Louis Vermeulen; Gerrit A Meijer; Evelien Dekker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-12       Impact factor: 46.802

8.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.

Authors:  Felipe De Sousa E Melo; Xin Wang; Marnix Jansen; Evelyn Fessler; Anne Trinh; Laura P M H de Rooij; Joan H de Jong; Onno J de Boer; Ronald van Leersum; Maarten F Bijlsma; Hans Rodermond; Maartje van der Heijden; Carel J M van Noesel; Jurriaan B Tuynman; Evelien Dekker; Florian Markowetz; Jan Paul Medema; Louis Vermeulen
Journal:  Nat Med       Date:  2013-04-14       Impact factor: 53.440

9.  PIK3CA and APC mutations are synergistic in the development of intestinal cancers.

Authors:  D A Deming; A A Leystra; L Nettekoven; C Sievers; D Miller; M Middlebrooks; L Clipson; D Albrecht; J Bacher; M K Washington; J Weichert; R B Halberg
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

10.  Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo.

Authors:  M Yu; P Trobridge; Y Wang; S Kanngurn; S M Morris; S Knoblaugh; W M Grady
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.